PC Jeweller To Issue Shares Worth Rs 1,510 Crore To Lenders To Pay Outstanding Debt
PC Jeweller Ltd. will issue preferential equity shares worth Rs 1,509.97 crore to its lenders to settle part of their outstanding debts. The preferential shares will be allotted to the lenders on a private placement basis.
The company will issue 5.17 crore shares to the consortium lenders under the non-promoter and public category at an issue price of Rs 292 per share, according to the exchange filing. The issue price is higher than the floor price in accordance with the regulations by SEBI.
The issuance of shares is subject to approval from shareholders and other regulators, the company added.
The company is looking to issue 1.76 crore shares to the State Bank of India and 82 lakh shares to the Union Bank of India. The other lenders include Punjab National Bank, Axis Bank Ltd., IndusInd Bank Ltd., Bank of India, IDBI Bank Ltd., Karur Vysya Bank, and Kotak Mahindra Bank. The company will also allot shares to Indian Overseas Bank, Canara Bank, Indian Bank, Bank of Baroda, and IDFC First Bank Ltd.
The firm has also taken note of a fine imposed by the BSE and NSE for non-compliance related to the composition of the board. The company has also paid a fine of Rs 96,760 to both NSE and BSE and made the necessary changes in the board to comply with the requirements.
The jewellery brand has also re-appointed Ramesh Kumar Sharma as a whole-time director of the company with effect from Feb. 7, 2025, for a period of three years.
PC Jeweller shares fell as much as 3.14% during the day to Rs 170 apiece on the NSE. The stock closed 2.14% higher at Rs 179.27 per share. This compares with a 0.13% advance in the benchmark Nifty 50. It has risen 482.05% and 256.76% year-to-date.
-
Where You Live Shapes How You Get To Work | The Reason Why
Two-wheelers are the most popular way to get to work in India, accounting for nearly 43% of workplace commutes.
-
High US Salaries, No Green Card Certainty: The Financial Calculation Facing Indian H-1B Families
The suspension of PERM processing at eight technology employers does not cancel existing H-1B visas. What it does is force a question many Indian families have been avoiding: is the US salary worth tying your career and family plans to one employer?
-
Unhedged Position: Can India See An Indonesia-Style Time Correction?
The Nifty is trading below levels it first clocked in 2024. Is there, then, as I have suggested in the headline, potential that the current time correction drags on painfully for the next three-five, even ten years?
-
Navigating Friction And Energy Realities: An Analysis Of Marco Rubio's October Visit To India
Occurring at a critical juncture marked by stalled trade negotiations and escalating geopolitical pressures over global energy supplies, the visit offers a profound window into modern US-India relations.
-
India Exports Capital. Why Not Export Trusteeship?
The big question, then, is whether India can build an institution that global borrowers, investors, banks, and lawyers can trust, even without an Indian connection.
-
France's Economy & Politics Are In Crisis | The Reason Why
Let's look at how the French economy and politics evolved under Nicolas Sarkozy, Franois Hollande and Emmanuel Macron.
-
You May Inherit The Business. You Must Earn Its Credibility.
Succession tests the founder's ability to share authority as much as it tests the next generation's readiness to assume it.
-
Signing Deals Is One Thing; Making Them Work Is Another | The Week In Whys
Sometimes, things don't turn out as planned. Indian companies have lost some bids to rivals, some projects won't produce until 2030.
-
FOMC Wall, PERM Suspension, Hospital Stocks | Talking Points This Week
A PERM suspension would directly affect green-card sponsorship rather than H-1B visas, so the near-term earnings impact could remain relatively limited. The key question is whether this marks a new phase in US scrutiny of Indian IT.
-
Everything, Everywhere, All At Once: Dalal Street's Week To Forget | Joining The Dots
Visa curbs, a Starlink spat and cancer drug caps: what connects this week's shocks for Indian markets